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Targeted genome editing using engineered nucleases can reliably generate defined genetic mutations,
although the range of off-target lesions caused by these techniques is unclear. Recent papers in Cell Stem
Cell perform high-coverage whole-genome sequencing to demonstrate the feasibility of obtaining correctly
targeted pluripotent stem cell clones with minimal unintended modifications.Customized nucleases have enabled
efficient and targeted genome editing in
awide variety of cell types and organisms,
including human pluripotent stem cells
(PSCs). Several classes of ‘‘designer’’ nu-
cleases are commonly used for genome
editing, including zinc finger nucleases
(ZFNs) (Urnov et al., 2010), transcription
activator effector nucleases (TALENs)
(Joung and Sander, 2013), and the
CRISPR-Cas9 RNA-guided nuclease sys-
tem (RGNs) (Sander and Joung, 2014).
DNA double-stranded breaks (DSBs)
induced by these customizable nucleases
can be repaired by one of two competing
pathways in the cell: error-prone non-
homologous end-joining (NHEJ), which
leads to variable length insertion/deletion
mutations (indels), or homology-directed
repair (HDR), which can be used to intro-
duce precise alterations directed by a ho-
mologous DNA template. Several studies
appearing in Cell Stem Cell examine
whether these technologies can be used
to generate single-cell clones bearing
alterations of interest without also in-
ducing unwanted off-target mutations
(Kiskinis et al., 2014; Smith et al., 2014;
Suzuki et al., 2014; Veres et al., 2014).
When modifying the genomes of cells
or organisms, a fundamental question
arises: does a given engineered nuclease
act at genomic locations other than its
intended site? This is critically important
because unintended, off-target modifica-
tions in cell populations can lead to unex-
pected functional consequences in both
research and therapeutic contexts, where
functional consequences of even low-
frequency mutations can be of significant
concern. A more focused question is
how often different genome modification
methods yield single-cell clones bearing
on-target site modifications without addi-tional off-target sitemutations. Theanswer
to this question is important for developing
cell-culture-based models of disease in
which one seeks to compare two isogenic
cell lines that differ only at the desired on-
target site. Smith et al., Suzuki et al., and
Veres et al. apply high-coverage whole-
genome sequencing (WGS) to provide
insights into this issue. Suzuki et al.
and Veres et al. achieved 603 genome
coverage and, together with Smith et al.,
who report 303 coverage, conclude
that mutations induced by these targeting
methodologies in individual human PSC
clones are relatively rare.
Veres et al. examined unintended
mutations arising from CRISPR-Cas9
RGN targeting of two loci (SORT1 and
LINC00116) and TALENs targeting
one locus (SORT1) in human PSCs. A
total of nine clones (three clones for
each nuclease/target combination) were
analyzed. After filtering low complexity
regions, homopolymer-associated indel
artifacts, and mutations present in the
parental cell line, they uncovered a num-
ber of single nucleotide variants (SNVs)
and indels across all nine clones, with 28
of these indels confirmed by Sanger
sequencing. In the clones that underwent
CRISPR-Cas9 targeting, no DNA se-
quences similar to the intended target
site (allowing up to six mismatches) were
found within 100 bp of these confirmed
indels. However, one clone generated
via TALEN targeting was found to contain
a likely nuclease-induced off-target
mutation at a site whose DNA sequence
contained seven mismatches relative to
the intended target sequence.
Suzuki et al. examined potential off-
target mutations generated after helper-
dependent adenoviral vector (HDAdV),
TALEN, or hybrid HDAdV/TALEN geneCell Stemcorrection of the HBB locus in a clonal
induced pluripotent stem cell (iPSC) line
derived from a patient with sickle cell dis-
ease. After filtering their data set for direct
repeats, homopolymers, and repetitive se-
quencesandcomparingagainstcandidate
TALEN off-target sites predicted by an
in silico method, they also found SNVs in
numbers similar to those found by Veres
et al. as well as a limited number of indels
that were not localized near sites that
obviously resembled the on-target site.
They note that one technical limitation of
high-throughput short-read sequencing
technologies is the high systematic error
associated with certain repetitive, low
complexity, or homopolymer sequences.
However, the filtering methods employed,
while removing many false positives, also
removed one of two true indels confirmed
by Sanger sequencing, suggesting that
these WGS approaches may miss some
bona fide indel mutations.
Taken together, these studies demon-
strate that it is possible to isolate single
human PSC clones that appear to have
very few, if any, strictly nuclease-associ-
ated mutations. Smith et al. in this issue,
as well as Kiskinis et al. in a recent paper
utilizing ALS patient-derived iPSC lines for
diseasemodeling, arrive at similar conclu-
sions by WGS of iPSC clones bearing
alterations induced by engineered ZFNs,
TALENs, or CRISPR-Cas RGNs (Kiskinis
et al., 2014; Smith et al., 2014). Thus,
despite the fact that off-target mutations
have been previously identified in large
populations of genome-edited cells,
collectively these four studies show that
this is not an impediment to identifying
single clones that bear the intended on-
target alteration and very few identifiable
unintended nuclease-mediated changes.
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strictly isogenic relative to their parental
lines because they also appear to have
acquired other genetic variation during
clonal expansion, which may account for
many of the SNVs and indels discovered.
Additional studies in which more cell
clones modified by nucleases targeted
to different sites will be needed to further
assess the generality of these findings.
Importantly, the full genome-wide
spectrum of off-target mutations induced
by engineered nucleases remains as yet
undefined by these studies. WGS is un-
likely to fully address this important issue
for at least two reasons. First, as observed
by Veres et al. and Suzuki et al., system-
atic sequencing artifacts can make it
difficult to discern nuclease-induced al-
terations, even with high fold-coverage
sequencing, and bioinformatic filtering
strategies can also remove some bona
fide mutations as well (Suzuki et al.,
2014). Second, WGS is currently imprac-
tical for identifying lower frequency off-
target mutations. For example, there is
only a 95% probability of identifying off-
target sites that are mutated with a fre-
quency of 40% when sequencing three
diploid single-cell clones (as was done
by Veres et al.), and off-target mutations
that occur with more modest frequencies,4 Cell Stem Cell 15, July 3, 2014 ª2014 Elsevsuch as 10%, would routinely be missed
in such experiments. Indeed, to have
a 95% chance of finding off-target muta-
tions that occur with frequencies of
10%, 1%, or 0.1% at least once, one
would need to sequence 15, 150, or
1,500 diploid single-cell clones, respec-
tively. Furthermore, the actual number
of genomes that would need to be
sequenced is higher because convinc-
ingly distinguishing bona fide nuclease-
induced mutations from those acquired
by routine culture of cells requires identi-
fying indels at a given site more than
once among a population of genomes.
Clearly, an unbiased, genome-wide
method that is also sensitive enough to
identify even lower frequency off-target ef-
fects is required toglobally definedesigner
nuclease specificities. While the field
awaits description of such an approach,
the findings of Veres et al., Suzuki et al.,
Smith et al., and Kiskinis et al. take an
important step forward in showing that it
is possible to identify individual nuclease-
modified cell lines that bear few, if any,
unwanted nuclease-induced alterations.
These findings will undoubtedly spur
further research on the use of genome-
edited human PSCs for disease modeling
and of genome-edited single-cell clones
for potential therapeutic applications.ier Inc.ACKNOWLEDGMENTS
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Human induced pluripotent stem cells represent a promising tool for investigating the underlying causes of
disease; however, this potential currently remains unfulfilled. In this issue of Cell Stem Cell, Yoon et al. (2014)
used iPSCs derived from patients harboring common genetic risk variants as the starting point to discover
novel insights into disease pathology.The successful reprograming of somatic
cells into induced pluripotent stem cells
(iPSCs) by Takahashi and Yamanaka
in 2006 was seen as a landmark event indisease research. This new technology
promised to provide a powerful tool for
modeling human pathology that could be
used to understand the underlying causesof various human diseases. The following
years saw a stream of new and improved
approaches for converting somatic cells
into more differentiated cell types such
